A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
Switching from daily 0.5mg dutasteride to three times a week may reduce side effects without worsening hair loss. Bloodwork showed no abnormalities, supporting the change.
Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.
RU58841 for hair loss, with users discussing sources, effectiveness, and side effects. Some users report side effects and question the long-term safety of RU58841.
Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.
The user reported significant hair regrowth and stopped hair loss after using Pyrilutamide and Minoxidil for four months. They found Pyrilutamide effective in blocking DHT locally without side effects, preferring a gray market version over Koshine's product.
A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.
Finasteride helped stop hair loss progression and slightly thickened hair, but reduced beard and chest hair growth. The user also uses ketoconazole shampoo for scalp itchiness.
The user is considering using RU58841 and pyrilutamide for hair loss, debating between powder and topical forms, and is currently using a combination of dutasteride, finasteride, minoxidil, tretinoin, and supplements. They report no significant side effects from finasteride and dutasteride, and are seeing some hair growth, but not on the scalp.
The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.